Tebbutt, N. C., Price, T. J., Ferraro, D. A., Wong, N., Veillard, A., Hall, M., . . . Gebski, V. (2016). Panitumumab added to docetaxel, cisplatin and fluoropyrimidine in oesophagogastric cancer: ATTAX3 phase II trial. Br J Cancer.
Chicago-stil citatTebbutt, Niall C., et al. "Panitumumab Added to Docetaxel, Cisplatin and Fluoropyrimidine in Oesophagogastric Cancer: ATTAX3 Phase II Trial." Br J Cancer 2016.
MLA-referensTebbutt, Niall C., et al. "Panitumumab Added to Docetaxel, Cisplatin and Fluoropyrimidine in Oesophagogastric Cancer: ATTAX3 Phase II Trial." Br J Cancer 2016.
Varning: dessa hänvisningar är inte alltid fullständigt riktiga.